Hospira gets FDA GMP warning for two plants
This article was originally published in Scrip
Executive Summary
The US FDA has hit Hospira, a maker of injectable pharmaceuticals and hospital products, with a warning letter for good manufacturing practice (GMP) violations at two plants.